Chemomab Therapeutics Ltd. (NASDAQ:CMMB)

Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.

See stocks that are scored

About CMMB

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

Address

Building C, Tel Aviv-Yafo, TA, 6158101, IL

Market Cap

9 million

Employees

Industrial Classification

Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying

Sold

$6.52K

Bought

$20.25K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score

Fair

From CMMB’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

Mar 10, 2027Earnings report

Ask Barron about CMMB

1 Day

+5.60%

5 Days

+8.20%

1 Month

-5.04%

6 Months

-25.42%

1 Year

-51.11%

$CMMB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Whale Activity →

Recently reported changes in CMMB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CMMB's directors and management

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CMMB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CMMB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CMMB from public contracts

Source: USAspending.gov

CMMB Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Net Selling

No open-market insider buying in the last 90 days — 1 insider sold $6.5K; insiders still hold ~0.0% of the company. The score reflects net insider selling.

Data completeness: 82%

Bull Case vs Bear Case

AI-generated from CMMB’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

0/ 100

Insider Activity

Open-market Form 4 buying

Neutral

Transaction Size

Purchase $ vs. market cap

Neutral

Insider Ownership

Stake increase by buyers

Neutral

Buyer Cluster

Multiple insiders buying together

Neutral

Track Record

Past insider-buy performance

Neutral

Market Timing

Timing vs. recent price trend

Strong

Biotech: 97 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 59.6

What’s Behind the Score

Insider Activity

60% of score

Analyst Ratings

40% of score

News & Sentiment

No data yet

—

Recent Insider Activity

Buys

Sells

Buy Value

$20.25K

Distinct Buyers

Insider Score Trend Over Time

+0.0 since Sep 1

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.